Profile data is unavailable for this security.
About the company
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
- Revenue in USD (TTM)127.63m
- Net income in USD-75.89m
- Incorporated2000
- Employees341.00
- LocationMacroGenics Inc9704 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (301) 251-5172
- Fax+1 (301) 251-5321
- Websitehttps://www.macrogenics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Korro Bio Inc | 7.37m | -88.42m | 108.30m | 87.00 | -- | 1.09 | -- | 14.69 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -25.79m | 109.76m | 29.00 | -- | 1,257.10 | -- | -- | -0.2868 | -0.2868 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 112.07m | 30.00 | -- | 1.37 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 114.94m | 44.00 | -- | 2.54 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Coya Therapeutics Inc | 3.99m | -18.43m | 115.13m | 8.00 | -- | 3.01 | -- | 28.87 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Equillium Inc | 4.39m | -24.42m | 116.92m | 35.00 | -- | 3.77 | -- | 26.62 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 119.10m | 33.00 | -- | 0.972 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 182.33k | -108.09m | 119.54m | 134.00 | -- | -- | -- | 655.65 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
| Agenus Inc | 106.83m | -35.38m | 120.71m | 316.00 | -- | -- | -- | 1.13 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 121.83m | 97.00 | -- | 1.13 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| MacroGenics Inc | 127.63m | -75.89m | 122.72m | 341.00 | -- | 1.83 | -- | 0.9616 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 123.38m | 32.00 | -- | 4.65 | -- | 3.04 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Genelux Corp | 0.00 | -31.87m | 130.56m | 24.00 | -- | 5.91 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.4943 | 0.00 | -- | -- | 0.00 | -97.69 | -125.27 | -116.81 | -- | -- | -- | -- | -830.46 | -- | -- | 0.00 | -- | -95.29 | -- | -5.56 | -- | -26.46 | -- |
| Cardiff Oncology Inc | 593.00k | -45.88m | 132.63m | 31.00 | -- | 2.92 | -- | 223.66 | -0.6873 | -0.6873 | 0.0089 | 0.6645 | 0.0075 | -- | 1.24 | 19,129.03 | -57.65 | -36.79 | -70.95 | -40.48 | -- | -- | -7,732.04 | -7,960.06 | -- | -- | 0.00 | -- | -13.18 | 10.13 | -0.9262 | -- | -26.97 | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 132.94m | 13.00 | 3.32 | 0.671 | 3.03 | 66.47 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Polaryx Therapeutics, Inc | -100.00bn | -100.00bn | 136.35m | 2.00 | -- | 25.72 | -- | -- | -- | -- | -- | 0.112 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -703.28 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to MacroGenics Inc's reporting currency: US Dollar USD
40.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2025 | 6.32m | 10.00% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.86m | 6.11% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 2.91m | 4.60% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 2.52m | 3.98% |
| Millennium Management LLCas of 31 Dec 2025 | 1.97m | 3.12% |
| Jefferies Investment Advisers LLCas of 31 Dec 2025 | 1.84m | 2.91% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 1.81m | 2.86% |
| Wasatch Advisors LPas of 31 Dec 2025 | 1.79m | 2.82% |
| Marshall Wace LLPas of 31 Dec 2025 | 1.28m | 2.03% |
| Jane Street Capital LLCas of 31 Dec 2025 | 1.25m | 1.98% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
